FDA approval
FDA approval means the agency reviewed a specific drug product for safety, effectiveness, and manufacturing quality for a specific indication. A compounded drug is not an FDA-approved drug.
Four phrases. Four different meanings.
A five-minute guide to advisory votes, FDA action, and the 503A Bulks List.
Advisory signalPEPLYST READOUT
What it means
An expert committee sent a non-binding recommendation to FDA.
What it does not mean
It is not FDA approval, final permission to compound, or proof that the peptide works.
→
What to watch next
Watch for an FDA proposal, enforcement policy, or final agency action.
503A compounding
Section 503A creates conditions under which qualifying patient-specific compounding can receive certain exemptions. Whether a bulk substance can be used depends on criteria including monographs, approved-drug components, and the 503A Bulks List.
PCAC recommendation
The Pharmacy Compounding Advisory Committee gives FDA expert, non-binding advice. A favorable vote is a process event—not approval and not, by itself, final permission to compound.
Proposed and final action
FDA may use notice-and-comment rulemaking to amend the 503A Bulks List. Proposed action signals intent; a final action is what changes the list.
The shortest useful version
Committee voteAdvice to FDA
Proposed ruleFDA’s stated intent, open to comment
Final rule/actionThe legally operative agency step
FDA approvalA separate drug-approval determination